Hypothalamic Menin restoration reverses multiple aging phenotypes in 20-month-old mice via D-serine pathway
Targeted restoration of hypothalamic Menin in aged mice improved bone density, skin thickness, and cognition through reduced inflammation and restored D-serine signaling. The 2023 PLOS Biology conditional-knockout and gene-delivery experiments provide causal evidence but remain limited to rodents and short treatment durations. Human translation will require primate safety data and confirmation that D-serine supplementation alone can achieve comparable peripheral benefits.
If replicated in larger mammals and shown to avoid hypothalamic dysregulation or oncogenic risk, Menin-targeted or D-serine-based interventions could enter early-phase trials focused on frailty or mild cognitive impairment within five years. The critical next evidence required is a longitudinal non-human primate study measuring both efficacy endpoints and hypothalamic inflammatory markers over at least six months.
HELIX: No phase-1 human trial of hypothalamic Menin AAV or chronic D-serine dosing for aging endpoints will begin before 2028.
Sources (3)
- [1]Primary Source(https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002036)
- [2]Supporting Source(https://www.nature.com/articles/s41574-023-00879-4)
- [3]Supporting Source(https://www.cell.com/neuron/fulltext/S0896-6273(22)00912-3)